H.C. Wainwright Remains a Buy on Inovio Pharmaceuticals (INO)


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO) today and set a price target of $13. The company’s shares closed yesterday at $5.43.

According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 5.7% and a 48.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inovio Pharmaceuticals with a $11 average price target, a 102.6% upside from current levels. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $8 price target.

.

See today’s analyst top recommended stocks >>

Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.64 million. In comparison, last year the company had a GAAP net loss of $9.48 million.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. Most recently, in July 2018, Peter Kies, the CFO of INO sold 35,000 shares for a total of $155,250.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts